News NICE backs Alimera’s three-year uveitis implant An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that can cau
Partner Content Partner Content Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 20... Ophthalmic Drugs Conference London
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
